SCHEMBL310023

SCHEMBL310023

COc1ccc(C(=O)O)c(C)c1C#N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 6/20 0.44
MYC P01106 1/20 0.43
NOTUM Q6P988 1/20 0.42
CDC25B P30305 1/20 0.42
LMNA P02545 2/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 5/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40
TPMT P51580 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14893974 0.87 ALDH1A1 (0.44) MAPTTDP1ALDH1A1NOTUMLMNA
SCHEMBL5110105 0.82 MAPT (0.46) MAPTTDP1ALDH1A1MYCNOTUM
SCHEMBL14894160 0.81 HPGDS (0.52) MAPTALDH1A1NOTUMLMNACYP2C9
SCHEMBL3107355 0.79 NOTUM (0.40) ALDH1A1NOTUMKDM4EHPGDHSD17B10
SCHEMBL27480737 0.78 FABP3 (0.50) MAPTTDP1ALDH1A1NOTUMCDC25B
SCHEMBL732725 0.78 MAPT (0.61) MAPTTDP1ALDH1A1MYCCDC25B
SCHEMBL1534071 0.78 ELANE (0.37) MAPTTDP1ALDH1A1NOTUMKDM4E
SCHEMBL2650251 0.77 CSNK2A1 (0.44) ALDH1A1MYCNOTUMHTTCA12
SCHEMBL28314003 0.77 ALDH1A1 (0.39) MAPTALDH1A1NOTUMKDM4EL3MBTL1
SCHEMBL8141458 0.76 NOTUM (0.49) MAPTTDP1ALDH1A1MYCNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
EP-1189879-A1 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2002-03-27 EP disclosed
EP-1183234-A1 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2002-03-06 EP disclosed
WO-2000071512-A1 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2000-11-30 WO disclosed
WO-2000071509-A1 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 MAPT 2367/4885TDP1 1064/4885ALDH1A1 3410/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 MAPT 2367/4885TDP1 1064/4885ALDH1A1 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.